{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T22:38:35Z","timestamp":1787611115833,"version":"build-2736575974"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,6,17]],"date-time":"2020-06-17T00:00:00Z","timestamp":1592352000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002661","name":"Fonds De La Recherche Scientifique - FNRS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010563","name":"Fonds Baillet Latour","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010563","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomaterials"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.biomaterials.2020.120209","type":"journal-article","created":{"date-parts":[[2020,6,17]],"date-time":"2020-06-17T16:36:23Z","timestamp":1592411783000},"page":"120209","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":53,"special_numbering":"C","title":["Targeted nanoparticles towards increased L cell stimulation as a strategy to improve oral peptide delivery in incretin-based diabetes treatment"],"prefix":"10.1016","volume":"255","author":[{"given":"Yining","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herlinde","family":"De Keersmaecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Braeckmans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefaan","family":"De Smedt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrice D.","family":"Cani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Pr\u00e9at","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Beloqui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.biomaterials.2020.120209_bib1","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.drudis.2014.10.003","article-title":"Peptide therapeutics: current status and future directions","volume":"20","author":"Fosgerau","year":"2015","journal-title":"Drug Discov. Today"},{"issue":"8","key":"10.1016\/j.biomaterials.2020.120209_bib2","doi-asserted-by":"crossref","first-page":"663","DOI":"10.4155\/tde-2017-0024","article-title":"Challenges in oral peptide delivery: lessons learnt from the clinic and future prospects","volume":"8","author":"Richard","year":"2017","journal-title":"Ther. Deliv."},{"key":"10.1016\/j.biomaterials.2020.120209_bib3","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jconrel.2018.08.032","article-title":"Oral peptide delivery: translational challenges due to physiological effects","volume":"287","author":"Tyagi","year":"2018","journal-title":"J. Contr. Release"},{"issue":"Pt B","key":"10.1016\/j.biomaterials.2020.120209_bib4","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.addr.2016.04.001","article-title":"Lipid-based nanocarriers for oral peptide delivery","volume":"106","author":"Niu","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"Pt B","key":"10.1016\/j.biomaterials.2020.120209_bib5","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.addr.2016.02.004","article-title":"Current status of selected oral peptide technologies in advanced preclinical development and in clinical trials","volume":"106","author":"Aguirre","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"3","key":"10.1016\/j.biomaterials.2020.120209_bib6","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1086\/517147","article-title":"Declining prevalence of cryptosporidiosis in san francisco","volume":"27","author":"Kim","year":"1998","journal-title":"Clin. Infect. Dis."},{"issue":"1","key":"10.1016\/j.biomaterials.2020.120209_bib7","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/BF00581038","article-title":"Insulinotropic actions of intravenous glucagon-like peptide-1 (GLP-1) [7-36 amide] in the fasting state in healthy subjects","volume":"32","author":"Qualmann","year":"1995","journal-title":"Acta Diabetol."},{"issue":"9","key":"10.1016\/j.biomaterials.2020.120209_bib8","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.2174\/1381612822666151216150238","article-title":"Delivery of peptides via the oral route: diabetes treatment by peptide-loaded nanoparticles","volume":"22","author":"Bouttefeux","year":"2016","journal-title":"Curr. Pharmaceut. Des."},{"issue":"Pt B","key":"10.1016\/j.biomaterials.2020.120209_bib9","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.addr.2016.10.005","article-title":"Oral delivery of peptides: opportunities and issues for translation","volume":"106","author":"Brayden","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.biomaterials.2020.120209_bib10","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/s41573-019-0053-0","article-title":"Advances in oral peptide therapeutics","volume":"19","author":"Drucker","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"issue":"5","key":"10.1016\/j.biomaterials.2020.120209_bib11","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1136\/gutjnl-2019-319146","article-title":"Novel strategy for oral peptide delivery in incretin-based diabetes treatment","volume":"69","author":"Xu","year":"2020","journal-title":"Gut"},{"issue":"18","key":"10.1016\/j.biomaterials.2020.120209_bib12","doi-asserted-by":"crossref","first-page":"1900610","DOI":"10.1002\/advs.201900610","article-title":"A proresolving peptide nanotherapy for site-specific treatment of inflammatory bowel disease by regulating proinflammatory microenvironment and gut microbiota","volume":"6","author":"Li","year":"2019","journal-title":"Adv. Sci."},{"issue":"51","key":"10.1016\/j.biomaterials.2020.120209_bib13","doi-asserted-by":"crossref","first-page":"44354","DOI":"10.1021\/acsami.8b20821","article-title":"Microfluidic nanoassembly of bioengineered chitosan-modified FcRn-targeted porous silicon nanoparticles @ hypromellose acetate succinate for oral delivery of antidiabetic peptides","volume":"10","author":"Martins","year":"2018","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.biomaterials.2020.120209_bib14","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.addr.2016.08.012","article-title":"Building the design, translation and development principles of polymeric nanomedicines using the case of clinically advanced poly(lactide(glycolide))-poly(ethylene glycol) nanotechnology as a model: an industrial viewpoint","volume":"107","author":"Lakkireddy","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"6","key":"10.1016\/j.biomaterials.2020.120209_bib15","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.addr.2013.01.002","article-title":"Targeted nanoparticles with novel non-peptidic ligands for oral delivery","volume":"65","author":"des Rieux","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"4","key":"10.1016\/j.biomaterials.2020.120209_bib16","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1016\/j.celrep.2014.10.032","article-title":"Bacterial metabolite indole modulates incretin secretion from intestinal enteroendocrine L cells","volume":"9","author":"Chimerel","year":"2014","journal-title":"Cell Rep."},{"issue":"13","key":"10.1016\/j.biomaterials.2020.120209_bib17","doi-asserted-by":"crossref","first-page":"11312","DOI":"10.1074\/jbc.M211609200","article-title":"The Orphan G protein-coupled receptors GPR41 and GPR43 are activated by propionate and other short chain carboxylic acids","volume":"278","author":"Brown","year":"2003","journal-title":"J. Biol. Chem."},{"issue":"28","key":"10.1016\/j.biomaterials.2020.120209_bib18","doi-asserted-by":"crossref","first-page":"25481","DOI":"10.1074\/jbc.M301403200","article-title":"Functional characterization of human receptors for short chain fatty acids and their role in polymorphonuclear cell activation","volume":"278","author":"Le Poul","year":"2003","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.biomaterials.2020.120209_bib19","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1079\/BJN20061853","article-title":"Butyrate production from oligofructose fermentation by the human faecal flora: what is the contribution of extracellular acetate and lactate?","volume":"96","author":"Morrison","year":"2006","journal-title":"Br. J. Nutr."},{"issue":"1\u20132","key":"10.1016\/j.biomaterials.2020.120209_bib20","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.ijpharm.2010.06.019","article-title":"Post-insertion into Lipid NanoCapsules (LNCs): from experimental aspects to mechanisms","volume":"396","author":"Perrier","year":"2010","journal-title":"Int. J. Pharm."},{"issue":"2","key":"10.1016\/j.biomaterials.2020.120209_bib21","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.jconrel.2013.05.035","article-title":"Scalable method to produce biodegradable nanoparticles that rapidly penetrate human mucus","volume":"170","author":"Xu","year":"2013","journal-title":"J. Contr. Release"},{"issue":"1","key":"10.1016\/j.biomaterials.2020.120209_bib22","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1021\/acs.molpharmaceut.7b00742","article-title":"Size effect on lipid nanocapsule-mediated GLP-1 secretion from enteroendocrine L cells","volume":"15","author":"Xu","year":"2018","journal-title":"Mol. Pharm."},{"issue":"14","key":"10.1016\/j.biomaterials.2020.120209_bib23","doi-asserted-by":"crossref","DOI":"10.21769\/BioProtoc.2394","article-title":"Analyzing the properties of murine intestinal mucins by electrophoresis and histology","volume":"7","author":"Wang","year":"2017","journal-title":"Bio. Protocol."},{"key":"10.1016\/j.biomaterials.2020.120209_bib24","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.addr.2017.08.010","article-title":"PEGylation for enhancing nanoparticle diffusion in mucus","volume":"124","author":"Huckaby","year":"2018","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"12","key":"10.1016\/j.biomaterials.2020.120209_bib25","doi-asserted-by":"crossref","first-page":"4222","DOI":"10.1021\/acs.molpharmaceut.6b00871","article-title":"A mechanistic study on nanoparticle-mediated glucagon-like peptide-1 (GLP-1) secretion from enteroendocrine L cells","volume":"13","author":"Beloqui","year":"2016","journal-title":"Mol. Pharm."},{"issue":"7","key":"10.1016\/j.biomaterials.2020.120209_bib26","doi-asserted-by":"crossref","first-page":"6996","DOI":"10.1021\/acsnano.5b01326","article-title":"Surface functionalization of nanoparticles with polyethylene glycol: effects on protein adsorption and cellular uptake","volume":"9","author":"Pelaz","year":"2015","journal-title":"ACS Nano"},{"issue":"2","key":"10.1016\/j.biomaterials.2020.120209_bib27","doi-asserted-by":"crossref","first-page":"364","DOI":"10.2337\/db11-1019","article-title":"Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein-coupled receptor FFAR2","volume":"61","author":"Tolhurst","year":"2012","journal-title":"Diabetes"},{"issue":"8","key":"10.1016\/j.biomaterials.2020.120209_bib28","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.2337\/db15-0060","article-title":"Genetic disruption of protein kinase STK25 ameliorates metabolic defects in a diet-induced type 2 diabetes model","volume":"64","author":"Amrutkar","year":"2015","journal-title":"Diabetes"},{"issue":"489","key":"10.1016\/j.biomaterials.2020.120209_bib29","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aav0120","article-title":"The short-chain fatty acid propionate increases glucagon and FABP4 production, impairing insulin action in mice and humans","volume":"11","author":"Tirosh","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.biomaterials.2020.120209_bib30","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/1758-5996-6-70","article-title":"Effects of high-fat diet and the anti-diabetic drug metformin on circulating GLP-1 and the relative number of intestinal L-cells","volume":"6","author":"Kappe","year":"2014","journal-title":"Diabetol. Metab. Syndrome"},{"key":"10.1016\/j.biomaterials.2020.120209_bib31","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s12986-016-0153-3","article-title":"Nutritional modulation of endogenous glucagon-like peptide-1 secretion: a review","volume":"13","author":"Bodnaruc","year":"2016","journal-title":"Nutr. Metab."}],"container-title":["Biomaterials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0142961220304555?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0142961220304555?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T16:57:22Z","timestamp":1758905842000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0142961220304555"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":31,"alternative-id":["S0142961220304555"],"URL":"https:\/\/doi.org\/10.1016\/j.biomaterials.2020.120209","relation":{},"ISSN":["0142-9612"],"issn-type":[{"value":"0142-9612","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeted nanoparticles towards increased L cell stimulation as a strategy to improve oral peptide delivery in incretin-based diabetes treatment","name":"articletitle","label":"Article Title"},{"value":"Biomaterials","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biomaterials.2020.120209","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"120209"}}